Apogee Therapeutics’ Post

📚New #JAPSCJournal Article📚 📄This article reviews the existing evidence on the use of mechanical circulatory support in non-emergency complex and high-risk PCI, the optimal timing of initiating #MCS and barriers to MCS use. 🔓Access the full article here 👉 https://ow.ly/I6Ws50Qb3BT 📊Given the risk of emergency MCS implantation during haemodynamic compromise, prophylactic MCS implantation should be considered in selected patients undergoing high-risk PCI #PCI #CardioEd

🫀 Treating In-Stent Restenosis 🫀 13 October, 17:05 - 17:50 CEST ✅ Explore thrombosis, in-stent stenosis, and IVUS. ✅ Learn Jetstream's effectiveness, safe in-stent techniques, and IVUS benefits. ✅ How do patients reach the Lab in the Acute Phase? ✅ Why and how to treat patients with Acute DVT using AngioJet™ Register now ➡️ https://ow.ly/z28650PUy3z This breakout is supported by Boston Scientific. #VIO2023

Transcatheter aortic valve replacement (#TAVR) with a supra-annular, self-expanding valve (SEV) was noninferior to TAVR with an intra-annular, balloon-expandable valve (BEV) with regard to clinical outcomes, and superior concerning bioprosthetic valve dysfunction, through 12 months in patients with symptomatic, severe aortic stenosis who have small aortic annuli, the SMART Trial shows. #ACC24

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN™* platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3wymm4S Risk Info: https://bit.ly/4aatMct TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/4aryVhk Risk Info: https://bit.ly/49AjEJz TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3J8N9HF Risk Info: https://bit.ly/3Jbw1kK TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

#Esmo23 closed with a final presidential session delivering even more NSCLC data - this time in EGFR mutant aNSCLC. Positive results from MARIPOSA and MARIPOSA-2 were presented; both trials meeting their primary endpoints (showing improvements in PFS above the respective standards of care). OS data remains immature. While on one hand the data generated whoops and cheers, on the other there is caution about widespread adoption of the new combinations - will we see a wide variation in opinion among oncologists? Concerns that exist relate to increased toxicities and the impact on patient QoL. There was a clear message that future treatment decisions should be individualised to the needs of the patients balancing the risk / benefit. And, as a result, oncologists appear to be siding with their current standards of care. I suspect the story won’t end here - OS data when mature may tip the balance, along with the possibility of subcutaneous amivantamab, and there is a hope that new predictive factors will emerge that help identify patients who need a more intensified upfront regimen…

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN™* platform at 1 year.¹ Explore the evidence: https://bit.ly/3QClH9n Risk Info: https://bit.ly/3WyhSWv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024

...and here is how to briefly present a FIRST, the first mini-oscillometer, a revolutionary diagnostic device !... in French... ..MGC Diagnostics International, MGC Diagnostics, Restech - Respiratory Technology

Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance. Valve choice makes a difference. The Evolut™ #TAVR system has a unique design that enables greater blood flow and improved outcomes compared to SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/442CAja #AorticStenosis #SMARTtrial Risk Info: https://bit.ly/4cSqvB4 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.